Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
EU CHMP backed Keytruda with Padcev for perioperative use in resectable muscle-invasive bladder cancer; European Commission decision due in Q4 2026. Recommendation follows Phase 3 KEYNOTE-B15, showing event-free survival hazard ratio 0.53; overall survival hazard ratio 0.65 versus chemotherapy. Disclaimer: This news br
Merck reported Phase 3 KEYNOTE-B15 results supporting perioperative Keytruda with Padcev in resectable muscle-invasive bladder cancer. Results were already reported in the CHMP briefing; no future scientific meeting presentation was specified. Trial showed fewer disease events and longer survival versus standard neoadj